ChromoGenics AB Statistics

Total Valuation

ChromoGenics AB has a market cap or net worth of SEK 64.85 million. The enterprise value is 85.06 million.

Market Cap	64.85M
Enterprise Value	85.06M

Important Dates

The last earnings date was Friday, November 22, 2024.

Earnings Date	Nov 22, 2024
Ex-Dividend Date	n/a

Share Statistics

ChromoGenics AB has 6.63 million shares outstanding. The number of shares has increased by 320.54% in one year.

Current Share Class	n/a
Shares Outstanding	6.63M
Shares Change (YoY)	+320.54%
Shares Change (QoQ)	+50.07%
Owned by Insiders (%)	45.32%
Owned by Institutions (%)	3.10%
Float	1.64M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.71
PB Ratio	0.96
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.56
EV / Sales	9.20
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.01

Financial Position

The company has a current ratio of 0.68, with a Debt / Equity ratio of 0.37.

Current Ratio	0.68
Quick Ratio	0.40
Debt / Equity	0.37
Debt / EBITDA	n/a
Debt / FCF	-0.59
Interest Coverage	-10.21

Financial Efficiency

Return on equity (ROE) is -31.37% and return on invested capital (ROIC) is -33.93%.

Return on Equity (ROE)	-31.37%
Return on Assets (ROA)	-26.26%
Return on Invested Capital (ROIC)	-33.93%
Return on Capital Employed (ROCE)	n/a
Revenue Per Employee	330,179
Profits Per Employee	-666,071
Employee Count	31
Asset Turnover	0.07
Inventory Turnover	1.11

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +54.75% in the last 52 weeks. The beta is 1.00, so ChromoGenics AB's price volatility has been similar to the market average.

Beta (5Y)	1.00
52-Week Price Change	+54.75%
50-Day Moving Average	9.87
200-Day Moving Average	8.34
Relative Strength Index (RSI)	49.26
Average Volume (20 Days)	14,267

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ChromoGenics AB had revenue of SEK 9.25 million and -18.65 million in losses. Loss per share was -4.22.

Revenue	9.25M
Gross Profit	-2.79M
Operating Income	-57.27M
Pretax Income	-18.65M
Net Income	-18.65M
EBITDA	-53.89M
EBIT	-57.27M
Loss Per Share	-4.22

Full Income Statement

Balance Sheet

The company has 4.73 million in cash and 24.94 million in debt, giving a net cash position of -20.21 million or -3.05 per share.

Cash & Cash Equivalents	4.73M
Total Debt	24.94M
Net Cash	-20.21M
Net Cash Per Share	-3.05
Equity (Book Value)	67.80M
Book Value Per Share	10.23
Working Capital	-10.79M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -42.15 million and capital expenditures -136,000, giving a free cash flow of -42.28 million.

Operating Cash Flow	-42.15M
Capital Expenditures	-136,000
Free Cash Flow	-42.28M
FCF Per Share	-6.38

Full Cash Flow Statement

Margins

Gross margin is -30.12%, with operating and profit margins of -619.46% and -201.73%.

Gross Margin	-30.12%
Operating Margin	-619.46%
Pretax Margin	-201.76%
Profit Margin	-201.73%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-457.34%

Dividends & Yields

ChromoGenics AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-320.54%
Shareholder Yield	-320.54%
Earnings Yield	-43.14%
FCF Yield	-65.20%

Stock Splits

The last stock split was on September 11, 2023. It was a reverse split with a ratio of 0.01.

Last Split Date	Sep 11, 2023
Split Type	Reverse
Split Ratio	0.01

Scores

ChromoGenics AB has an Altman Z-Score of -8.73. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-8.73
Piotroski F-Score	n/a